The immune system does not fight cancer (no antibodies form against it), which shows the body accepts the tumour; therefore attacking it with chemotherapy is wrong.
Original statement
جسمك ما حاروش ليه وما عملش ليه ضده اجسام مضاده
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
The immune system does not fight cancer (no antibodies form against it), which shows the body accepts the tumour; therefore attacking it with chemotherapy is wrong.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! (Open source)
- Published
- 16 March 2025
- Timestamp
- 0:14:27 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Diverging source versions
يقول لنا ليه السرطان ما بيطلعش ضده جسم مضاد
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! التراكمي عال و السكر واطيي (Open source)
- Published
- 5 October 2025
- Timestamp
- 0:37:43 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
No immune response to cancer; the body tolerates it on purpose.
2. What is demonstrably correct?
Tumours evade immune control (e.g., via checkpoint pathways) and grow despite lymph-node passage; this is a real research topic.
3. What is wrong or exaggerated?
Releasing immune checkpoints lets T cells control metastatic melanoma in many patients (5-year survival 52% vs 26%; I-CHM-08). Immune evasion is a mechanism of cancer, not a sign that the tumour is beneficial.
4. What remains unclear?
Why some cancers respond to immunotherapy and others do not is still being studied; the cited trial concerns metastatic melanoma (I-CHM-08).
5. Which studies support it?
None for the conclusion. The kernel that tumours evade immune control (for example via checkpoint pathways) is real; checkpoint-inhibitor therapy (I-CHM-08) is built on it.
6. Which studies contradict it?
7. What applies to Germany and Europe?
Not region-specific; checkpoint immunotherapy is used in European oncology for several cancers (not audited in detail).
8. What is known about Egypt?
Not region-specific; access to immunotherapy in Egypt was not reviewed.
9. What practical conclusion is appropriate?
Immunotherapy is an option for some cancers, chosen by oncologists.
Assessment details
- Rationale for certainty of evidence
Immune evasion by tumours is real, but randomised immunotherapy trials show the immune system can control cancer; the conclusion against treatment does not follow.
- Source quality
Machine transcripts.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Dr. Diaa argued that the body does not fight cancer and therefore wants it. In fact, cancers grow partly because they switch off immune defences. Modern drugs that remove these 'brakes' let the immune system attack the cancer, and half of patients with advanced melanoma were alive after five years.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (1)
-
Immunotherapy lets half of patients with advanced melanoma live at least five years
Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836Randomised controlled trialindependent cross-checkabstract only checked5-year survival 52% with combined immunotherapy vs 26% with the older drug.
T cells can control cancer
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Report 5-year survival.
- How was the study done?
RCT.
- How many people, animals or samples were studied?
Advanced melanoma.
- What was actually found?
52% 5-year OS.
- How large was the observed effect?
HR 0.52.
- What do the results mean in everyday life?
The immune system can fight cancer when helped.
- What are the study's limitations?
Industry funding.
- What does it say about Elawady's specific claim?
Contradicts immune claim.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effect in other cancers.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Not region-specific; checkpoint immunotherapy is used in European oncology for several cancers (not audited in detail).
Egypt
Not region-specific; access to immunotherapy in Egypt was not reviewed.
What applies in my country?
General scientific assessment
Mostly false Immune evasion is a feature of cancer, not proof that the body wants the tumour.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.. Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836